NCT01751763View on ClinicalTrials.gov

Sorafenib for Residue Disease After Resection With Curative Intent

CompletedOBSERVATIONAL

Enrollment

106

Participants

Timeline

Start Date

July 9, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

September 8, 2017

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

treatment (including dose, duration, modification) decided by the investigator.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY